John M Burke, MD from Rocky Mountain Cancer Centers discusses further promising studies in 2018 – CAR-T cell therapy, Polatuzumab, checkpoint inhibitorsat the 2017 American Society of Hematology.
Further Promising Studies in 2018 – CAR-T Cell Therapy, Polatuzumab, Checkpoint Inhibitors
